Why the 2026 LiBBY Trial Does Not Establish Routine THC-CBD Care: What the Findings Mean for Rural Dementia Families

Small hospice trial cut agitation, but safety risks mean rural families need supervised hospice guidance.

The 2026 LiBBY trial does not establish routine THC-CBD care because it enrolled only 120 hospice-eligible people with late-stage dementia. For rural families, it offers a supervised hospice option to discuss, not a retail product to try at home. LiBBY means Life's End Benefits of cannabidiol and tetrahydrocannabinol. THC is tetrahydrocannabinol, CBD is cannabidiol, and agitation means restlessness, aggression, or distress that threatens comfort and safety.

Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.

Table of Contents

What LiBBY tested

The Alzheimer's Association describes LiBBY as a 12-week, multicenter, randomized, double-blind, placebo-controlled Phase 2 study Alzheimer's Association AAIC announcement. It enrolled 120 hospice-eligible people with Alzheimer's or other dementias and major agitation across 10 U.S. sites.

Visits took place in homes or residences. Pennington Biomedical Research Center reports the formula was oral T2:C100, 2 mg THC plus 100 mg CBD in digestible oil twice daily. It rose to 4 mg THC plus 200 mg CBD twice daily during weeks 2-12. Study visits followed patients in homes or residences.

What improved and what raised concern

NeurologyLive, reporting the AAIC developing-topics session, states agitation scores fell 10.61 points on T2:C100 versus 4.35 points on placebo at week 2 NeurologyLive report on the AAIC session. The gap was highly unlikely to reflect chance alone (p=0.0004). Separation lasted through week 12. Clinicians rated global improvement in 83.9% of treated patients versus 30.5% on placebo at week 2.

By week 12, the figures were 87.2% versus 23.6% (p<0.0001). In daily terms, that points to calmer behavior and easier caregiving, not a cure for dementia. The same NeurologyLive report notes overall adverse events were similar, but serious events were higher with T2:C100. Serious adverse events reached 23.3% versus 11.9%, driven by serious infections at 11.7% versus 1.7%. Deaths reached 13.1% versus 5.1% in this frail end-of-life group.

Why this is not routine care

The ClinicalTrials.gov registry lists LiBBY as NCT05644262, a small Phase 2 hospice-only study. Results came as topline conference findings, not a larger confirmatory trial. Routine care needs larger trials, longer follow-up, and safety clarity in frail elders.

The FDA states its approved cannabis-derived medicines are limited to Epidiolex for Lennox-Gastaut, Dravet and tuberous sclerosis seizures plus synthetic THC-related drugs FDA cannabis regulation page. It has approved no cannabis product as safe and effective for dementia agitation. Trial clinicians, as reported by NeurologyLive, limit the finding to a purified, supervised formulation and dosing system.

What rural families can do now

AJMC, reporting a JAMA research letter on 2013-2022 Medicare decedents, finds rural dementia families used hospice less AJMC report on the JAMA research letter. Use was 44.8% for isolated-rural versus 52.4% for urban decedents. High-intensity care was also lower, including general inpatient care at 12.7% versus 21.1% and continuous home care at 0.5% versus 2.5%.

Families should discuss agitation only through hospice or palliative clinicians rather than substituting retail products. Trial clinicians stressed retail or over-the-counter cannabinoids differ from the purified study oil. Call the hospice nurse early when agitation rises, especially after hours. Bring a current medication list and a brief note on when agitation peaks to that visit.

  • Ask the hospice team what non-drug steps fit late-stage agitation
  • Bring a current medication list and notes on when distress peaks
  • Do not replace prescribed comfort care with dispensary oils or edibles
  • Ask how the team watches for fever, infection, falls, and sedation

You Might Also Like

HelpDementia.com

Dementia, Alzheimer's, Caregiving & Healthy Aging Guidance

© 2026 HelpDementia.com. All rights reserved.

Educational information only. It is not medical advice and does not replace care from a qualified clinician.